Optimal management of behavioural disorders associated with dementia

Drugs and Aging

Volumn 10, Issue 2, 1997, Pages 95-106

  Class, C Andrew ^a   Schneider, Lon ^b   Farlow, Martin R ^a  

^a INDIANA UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

AGED; AGITATION; AMNESIA; BEHAVIOR DISORDER; COGNITIVE DEFECT; DEMENTIA; DEPRESSION; DRUG EFFICACY; HOSPITAL ADMISSION; HUMAN; NURSING HOME; PALLIATIVE THERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SLEEP DISORDER; SYMPTOM;

EID: 0031040888     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199710020-00003     Document Type: Review

References (70)

1. Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer's disease in a community population of older persons: higher than previously reported. JAMA 1989; 262: 2551-6
2. Rovner BW, German PS, Broadhead J, et al. The prevalence and management of dementia and other psychiatric disorders in nursing homes. Int Psychogeriatrics 1990; 2: 13-24
3. Swearer JM, Drachman DA, O'Donnell BF, et al. Troublesome and disruptive behaviors in dementia: relationships to diagnosis and disease severity. J Am Geriatr Soc 1988; 36: 784-90
4. Cohen-Mansfield J. Agitated behaviors in the elderly: II. Preliminary results in the cognitively deteriorated. J Am Geriatr Soc 1986; 34: 722-7
5. Tariot PN, Podgorski CA, Blazina L, et al. Mental disorders in the nursing home: another perspective. Am J Psychiatry 1993; 150: 1063-9
6. Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer's disease: IV. Disorders of behaviour. Br J Psychiatry 1990; 157: 86-94
7. Pruchno RA, Michaels JE, Potashnik S. Predictors of institutionalization among Alzheimer disease victims with caregiving spouses. J Gerontol 1990; 45 Suppl. 6: S259-66
8. Giacobini E, Becker R. Present progress and future development in the therapy for Alzheimer's disease. In: Iqbal K, Wisniewski HM, Winblad B, editors. Alzheimer's disease and related disorders. New York: Alan R. Liss Inc., 1989: 1121-54
9. Farlow MR, Gracon SI, Hershey LA, et al. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992; 268: 2523-9
10. Rogers SL, Teaneck NJ, Doody R, et al. E2020 produces both clinical global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease: results of a 30-week phase 111 trial [abstract]. Neurology 1996; 46 Suppl. 48: A217
11. Eaggers SA, Levy R, Sahakian BJ. Tacrine in Alzheimer's disease. Lancet 1991; 337: 989-92
12. Knapp MM, Knopman DS, Soloman PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994; 271: 985-91
13. Cummings JL, Victoroff JI. Noncognitive neuropsychiatric syndromes in Alzheimer's disease. Neuropsychiatry Neuropsychol Behav Neurol 1990; 3: 140-58
14. Eichelman B. Toward a rational pharmacotherapy for aggressive and violent behavior. Hosp Community Psychiatry 1988; 39: 31-9
15. Zweig RM, Ross CA, Hedreen JC, et al. The neuropathology of aminergic nuclei in Alzheimer's disease. Ann Neurol 1988; 24: 233-42
16. Zubenko GS, Moossy J. Major depression in primary dementia: clinical and neuropathologic correlates. Arch Neurol 1988; 45: 1182-6
17. Zubenko GS, Moossy J, Kopp U. Neurochemical correlates of major depression in primary dementia. Arch Neurol 1990; 47: 209-14
18. Stewart JT. Managing the care of patients with dementia: how to maximize level of functioning and minimize behavior problems. Postgrad Med 1991; 90: 45-9
19. Malone ML, Thompson L, Goodwin JS. Aggressive behaviors among the institutionalized elderly. J Am Geriatr Soc 1993; 41: 853-6
20. Schneider LS, Pollock VE, Lyness SA. A metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990; 38: 553-63
21. Sunderland T, Weingartner H, Cohen RM, et al. Low-dose oral lorazepam administration in Alzheimer subjects and age-matched controls. Psychopharmacology (Berl) 1989; 99: 129-33
22. Sunderland T, Tariot PN, Newhouse PA. Differential responsivity of mood, behavior, and cognition to cholinergic agents in elderly neuropsychiatrie populations. Brain Res Rev 1988; 13: 371-89
23. Devanand DP, Brockington CD, Moody BJ. Behavioral syndromes in Alzheimer's disease. Int Psychogeriatrics 1992; 4: 161-84
24. Ancill RJ, Embury GD, MacEwan GW, et al. The use and misuse of psychotropic prescribing for elderly psychiatric patients. Can J Psychiatry 1988; 33: 585-9
25. Barnes R, Veith R, Okimoto J, et al. Efficacy of antipsychotic medications in behaviorally disturbed dementia patients. Am J Psychiatry 1982; 139: 1170-4
26. Peabody CA, Warner MD, Whiteford HA, et al. Neuroleptics and the elderly. J Am Geriatr Soc 1987; 35: 233-8
27. Steele C, Lucas MJ, Tune L. Haloperidol versus thioridazine in the treatment of behavioral symptoms in senile dementia of the Alzheimer's type: preliminary findings. J Clin Psychiatry 1986; 47: 310-2
28. Devanand DP, Sackeim HA, Brown RP, et al. A pilot study of haloperidol treatment of psychosis and behavioral disturbance in Alzheimer's disease. Arch Neurol 1989; 46: 854-7
29. Wragg RE, Jeste DV. Neuroleptics and alternative treatments: management of behavioral symptoms and psychosis in Alzheimer's disease and related conditions. Psychiatry Clin North Am 1988; 11: 195-213
30. Stotsky B. Multicenter study comparing thioridazine with diazepam and placebo in elderly, nonpsychotic patients with emotional and behavioral disorders. Clin Ther 1984; 6: 546-59
31. Goldberg RJ, Goldberg JS. Low-dose risperidone for dementia related disturbed behavior in nursing homes [abstract]. APA Annual Meeting 1995; Suppl.: 126
32. Madhusoodanan S, Brenner R, Araujo L, et al. Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder or senile dementia in 11 geriatric patients: a case series. J Clin Psychiatry 1995; 56 (11): 514-8
33. Patterson JF. A preliminary study of carbamazepine in the treatment of assaultive patients with dementia. J Geriatr Psychiatry Neurol 1988; 1: 21-3
34. Gleason RP, Schneider LS. Carbamazepine treatment of agitation in Alzheimer's outpatients refractory to neuroleptics. J Clin Psychiatry 1990; 51: 115-8
35. Tariot PN, Erb R, Leibovici A, et al. Carbamazepine treatment of agitation in nursing home patients with dementia: a preliminary study. J Am Geriatr Soc 1994; 42: 1160-6
36. Mellow AM, Solano-Lopez C, Davis S. Sodium valproate in the treatment of behavioral disturbance in dementia. J Geriatr Psychiatr Neurol 1993; 6 (4): 205-9
37. Patel S, Tariot PN. Use of benzodiazepines in behaviorally disturbed patients: risk-benefit ratio. In: Lawlor BA, editor. Behavioral complications in Alzheimer's disease. Washington, DC: American Psychiatric Press, 1995: 153-70
38. Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA 1989; 262 (23): 3303-7
39. Schneider LS, Sobin PB. Non-neuroleptic medications in the management of agitation in Alzheimer's disease and other dementia: a selective review. Int J Geriatr Psychiatry 1991; 6: 691-708
40. Weiler PG, Mungas D, Bernick C. Propranolol for the control of disruptive behavior in senile dementia. J Geriatr Psychiatr Neurol 1988; 1: 226-30
41. Young RC, Meyer BS. Psychopharmacology. In: Sadavoy J, Lazarus LW, Jarvik LF, editors. Comprehensive review of geriatric psychiatry. Washington, DC: American Psychiatric Press, 1991: 435-67
42. Ellison JM, Milofsky JE, Ely E. Fluoxetine-induced bradycardia and syncope in two patients. J Clin Psychiatr 1990; 51: 385-6
43. Marinkovic D, Totic S, Babinski T, et al. The extrapyramidal side-effects of selective serotonin re-uptake inhibitors. Hum Psychopharmacol 1995; 10: 158-9
44. Brymer C, Winograd CH. Fluoxetine in elderly patients: is there cause for concern? J Am Geriatr Soc 1992; 40: 902-5
45. Reynolds III CF, Perel JM, Kupfer DJ, et al. Open-trial response to antidepressant treatment in elderly patients with mixed depression and cognitive impairment. Psychiatry Res 1987; 21: 111-22
46. Sakauye KM, Camp CJ, Ford PA. Effects of buspirone on agitation associated with dementia. Am J Geriatr Psychiatry 1993; 1: 82-4
47. Levy MA, Burgio LD, Sweet R, et al. A trial of buspirone for the control of disruptive behaviors in community-dwelling patients with dementia. Int J Geriatr Psychiatry 1994; 9: 841-8
48. Lawlor BA, Radcliffe J, Molchan SE, et al. A pilot placebo-controlled study of trazodone and buspirone in Alzheimer's disease. Int J Geriatr Psychiatry 1994; 9 (1): 55-9
49. Aisen PS, Johannessen DJ, Marin DB. Trazodone for behavioral disturbance in Alzheimer's disease. Am J Geriatr Psychiatr 1993; 1 (4): 349-50
50. Simpson DM, Foster D. Improvement in organically disturbed behavior with trazodone treatment. J Clin Psychiatry 1986; 47: 191-3
51. Shaw SH, Carson H, Coquelin JP. A double-blind, comparative study of zolpidem and placebo in the treatment of insomnia in elderly psychiatric in-patients. J Int Med Res 1991; 20: 150-61
52. Wragg RE, Jeste DV. Overview of depression and psychosis in Alzheimer's disease. Am J Psychiatry 1989; 146: 577-87
53. Raskind MA. Management of late-life depression and the noncognitive behavioral disturbances of Alzheimer's disease. Psychiatry Clin North Am 1993; 16 (4): 815-27
54. Thapa PB, Meador KG, Gideon P, et al. Effects of antipsychotic withdrawal in elderly nursing home residents. J Am Geriatr Soc 1994; 42: 280-6
55. Horwitz GJ, Tariot PN, Mead K, et al. Discontinuation of antipsychotics in nursing home patients with dementia. Am J Geriatr Psychiatry 1995; 3 (4): 290-9
56. Factor SA, Brown D, Molho ES, et al. Clozapine: a 2-year open trial in Parkinson's disease patients with psychosis. Neurology 1994; 44: 544-6
57. Data on file, Lilly Research Laboratories
58. Schneider LS, Gleason R, Zemansky MF, et al. L-Deprenyl in Alzheimer's disease [abstract]. Gerontologist 1989; 28: 2A
59. Tariot PN, Cohen RM, Sunderland T, et al. L-deprenyl in Alzheimer's disease: preliminary evidence for behavioral change with monoamine oxidase B inhibition. Arch Gen Psychiatry 1987; 44: 427-33
60. Larson E, Reifler B, Sumi S, et al. Diagnostic evaluation of 200 elderly outpatients with suspected dementia. J Gerontol 1985; 40 (5): 536-43
61. Rovner BW, Broadhead J, Spencer M, et al. Depression and Alzheimer's disease. Am J Psychiatry 1989; 146: 350-3
62. Teri L, Gallagher-Thompson D. Cognitive-behavioral interventions for treatment of depression in Alzheimer's patients. Gerontologist 1991; 31 (3): 413-6
63. Greenwald BS, Kramer-Ginsberg E, Marin DB, et al. Dementia with coexistent major depression. Am J Psychiatry 1989; 146: 1472-8
64. Reifler BV, Teri L, Raskind M, et al. Double-blind trial of imipramine in Alzheimer's disease patients with and without depression. Am J Psychiatry 1989; 146: 45-9
65. Gottfries CG, Karlsson I, Nyth AL. Treatment of depression in elderly patients with and without dementia disorders. Int Clin Psychopharmacol 1992; 6: 55-64
66. Burke WJ, Folks DG, Roccaforte WH, et al. Serotonin reuptake inhibitors for the treatment of coexisting depression and psychosis in dementia of the Alzheimer type. Am J Geriatr Psychiatry 1994; 2 (4): 352-4
67. Nelson JP, Rosenberg DR. ECT treatment of demented elderly patients with major depression: a retrospective study of efficacy and safety. Convuls Ther 1991; 7 (3): 157-65
68. Vitiello MV, Prinz PN, Williams DE, et al. Sleep disturbances in patients with mild-stage Alzheimer's disease. J Gerontol 1990; 45 (4): M131-8
69. Mishima K, Okawa M, Hishikawa Y, et al. Morning bright light therapy for sleep and behavior disorders in elderly patients with dementia. Acta Psychiatr Scand 1994; 89: 1-7
70. Satlin A, Volicer L, Ross V, et al. Bright light treatment of behavioral and sleep disturbances in patients with Alzheimer's disease. Am J Psychiatry 1992; 149: 1028-32